Quarterly Outlook
Q4 Outlook for Investors: Diversify like it’s 2025 – don’t fall for déjà vu
Jacob Falkencrone
Global Head of Investment Strategy
Investment Strategist
A rotation in market leadership is underway. Sectors that lagged into August have bounced hard from their summer lows. Basic Resources, Technology, Healthcare and Luxury Goods have gained roughly 26%, 13%, 12% and 20% since then.
Momentum has underperformed as leadership broadened. Quality has retaken the wheel, led by the ‘GRANOLAS’ group of European heavyweights. A pause in EUR strength and easier bond yields removed headwinds for globally exposed franchises.
The result is a cleaner market that rewards delivery and strong fundamentals, not labels. Investors have shifted from stories to results. The winners pair clean inventories, firmer orders and tight execution. Call it the delivery trade. In short, execution and cash flow outweigh labels and tales.
GRANOLAS is Goldman Sachs’s nickname for eleven European leaders: GSK, Roche, ASML, Nestlé, Novartis, Novo Nordisk, L’Oréal, LVMH, AstraZeneca, SAP and Sanofi. They share classic quality traits such as resilient margins, high returns on capital, and global sales. They also matter for index leadership because of their size and liquidity. Healthcare within the group is nuanced, with obesity and oncology strength offset by pricing pressure and patent cycles.
The last twelve months were tough. A weaker dollar hurt exporters when revenues were translated back. A steeper yield curve and improving 2026 growth hopes pulled investors toward financials, industrials, defence and other cyclicals. Stock specifics added friction. Luxury faced choppy China demand and stricter inventory discipline. Semiconductors dealt with export rules and delivery timing worries. Healthcare saw pricing headlines and trial noise. Staples managed input cost swings and portfolio clean-ups. Put together, quality fell out of favour and the GRANOLAS lagged.
Macro set the backdrop, not the outcome. Currency and yield shifts nudge relative winners and losers, but this rotation did not hinge on one macro lever. The euro wobbled in October but did not run, giving exporters and tourism a lift rather than a rocket. Bond yields eased from recent peaks, which helps longer-duration stories like luxury and high-quality tech. Yet the biggest moves landed on results days, not during rate chatter.
Valuation looks reasonable. On about 19x average forward price-to-earnings vs the STOXX 50 at 17x, the group trades at a modest premium to the market for businesses with pricing power and high returns.
Three prints did the heavy lifting. LVMH jumped 12% on 15 October as growth returned in the third quarter. ASML rose 3% after stronger-than-expected bookings tied to artificial intelligence capacity. Nestlé rallied 9.3% on 16 October as investors cheered a reset under incoming leadership. The market read these as proof points that quality with global revenues still compounds when execution shows up.
These three are bellwethers. LVMH sets the tone for luxury demand and pricing power. ASML is the capacity gatekeeper for semiconductors. Nestlé anchors staples with scale and resilient cash flows. Their beats and guidance shape sector sentiment fast, so the rotation’s credibility rests on their delivery.
Leadership concentration is risky when it rests on narrow momentum. This rotation looks broader. The winners span luxury, chips and staples, and the drivers are business-specific rather than a single macro factor. That lowers the chance that one data point breaks the whole trade. For portfolios, the lesson is clear. The market is paying for delivery, cash-flow durability and global pricing power.
Earnings beat scepticism. LVMH’s update ended a two-quarter lull and lifted the whole luxury complex. Expectations were muted after a soft first half and stop-start China demand. The bar was low: stabilisation, clean inventory, and fewer promotions. The update delivered exactly that, with growth back in the third quarter and firmer full-price sell-through. Read-across: luxury pricing power still works when the product mix is right. That lifted peers and improved confidence in holiday sell-through.
AI capex ripples through the stack. ASML’s orders surprised on the upside, signalling that both foundries and memory makers are locking in tools to serve data-centre demand. Management framed demand as multi-year, with tool shipments and grid hookups now the real bottlenecks. Read-across: the capital-expenditure flywheel is intact. When ASML’s order book improves, suppliers and chipmakers usually follow. Supply chains read this as a capacity green light into 2026.
Staples reset and refocus. Nestlé’s 9.3% single-day gain flagged that cost discipline and portfolio optimisation can still unlock value in a slower-growth world. The market wanted a cleaner plan and tighter cost control from incoming leadership. It got a reset: sharper focus, faster decisions, and clearer priorities. Read-across: staples with scale and discipline can still re-rate without a growth boom.
China demand. A setback in travel or local consumption would dent luxury and staples. Track monthly mainland sales signals from listed peers and management commentary.
AI capex timing. Any push-out of data-centre projects, grid connections or memory expansions would filter quickly to tool orders. Follow order phasing and capex updates from top customers.
Policy and rates noise. Trade headlines can shift factor leadership in days. A stronger dollar or a jump in long yields would challenge globally exposed quality stocks.
GRANOLAS crowding. Positioning is heavy. A rates back-up, EUR strength, or small earnings misses could force de-crowding. Watch valuation spreads, factor flows, futures and ETF positioning, and guidance revisions.
Europe’s baton is moving from narrow momentum to broad, repeatable delivery. LVMH showed full-price demand still pays. ASML confirmed the AI capex engine is alive. Nestlé proved scale plus discipline can re-rate. That mix matters more than a soft euro or a kinder yield curve.
What keeps this into November is simple. Clean holiday sell-through at top luxury houses. Order cadence and on-time tool shipments across the chip stack. Portfolio focus and margin progress at the staples leaders. Healthcare remains nuanced, with obesity and oncology winners offset by pricing and patent cycles.
For investors, the homework is clear. Track delivery cadence, not slogans. Watch guidance tone more than macro headlines. Use earnings-day reactions as live signals of who is leading now. The loop closes where it started: in a noisy backdrop, real results beat narratives.